Adma Biologics, Inc. (ADMA) Stock Price & Analysis

Adma Biologics, Inc. (ADMA) rose 0.42% to USD 9.62 as of September 8, 2026 at 09:01 UTC, according to Nexqual real-time market data.

ADMA last closed at USD 9.62; the session ranged USD 9.39–9.62 on volume of 1,405,858 shares. Market capitalization is —, with a 52-week range of USD 7.21–20.46 (NGM). Source: Nexqual, September 8, 2026 at 09:01 UTC.

Key Statistics (as of September 8, 2026 at 09:01 UTC)

Technical Analysis (ADMA)

Nexqual's technical model rates ADMA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 09:01 UTC.

From Adma Biologics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• The end-to-end production cycle can take approximately seven to 12 months for a batch of FDA released drug product.
• We anticipate submitting a pre-Investigational New Drug (IND) package to the FDA in fiscal year 2026, which could enable us to progress development of SG-001 directly into a registrational clinical trial.
• As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus ("RSV") using our proprietary microneutralization testing assay.
• Utilizing our intellectual property patents, which include our proprietary testing assay and other standardization methods and technologies, we have identified potential new product candidates that we may advance into preclinical activities.

Partnerships

• Effective October 1, 2024, we entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the "A&R Grifols Agreement") with a term expiring in September 2039, after which it may be renewed for two additional multi-year periods if agreed to by the parties.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:01 UTC. This page is informational and not investment advice.